# Platform designation for ADC linker-payloads so manufacturing data carry across

Source: https://onco.cc/ideas/idea-reg-adc-platform-designation/  
OnCo record `idea-reg-adc-platform-designation` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Antibody-drug conjugates built on the same linker and payload, such as deruxtecan or vedotin, share the same conjugation process, payload synthesis, impurity profile and much of the toxicology. FDA, EMA and PMDA should designate these linker-payloads as platforms so a new ADC files only antibody-specific manufacturing and toxicology data.

## Summary

FDA's platform technology designation programme (draft guidance 2024, from the 2022 omnibus legislation) allows a well-characterised technology used in an approved product to be referenced in later applications. ADC linker-payloads (deruxtecan, vedotin, site-specific enzymatic conjugation from Synaffix or Araris) are natural platforms: the conjugation process, payload synthesis, impurity profile and much of the non-clinical toxicology are antibody-independent. The proposal is for FDA, EMA and PMDA to jointly designate ADC linker-payload platforms and publish what data may be referenced, so a new ADC on a designated platform files only antibody-specific CMC and toxicology.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: ADCs filed on a designated platform reach IND with at least 40% less non-clinical and CMC work and show no higher rate of clinical holds or manufacturing-related deficiencies than conventionally filed ADCs.
- Rationale: Deruxtecan has now been carried by many antibodies with a consistent payload toxicity profile; repeating payload characterisation per product adds cost without information. Platform reuse is how vaccines and gene therapy vectors are increasingly regulated.
- Proposed test: Designate two or three linker-payload platforms in a pilot, track IND timelines and deficiency letters for products using them against matched ADCs, and publish the outcomes.
- Maturity: early-clinical
- Actor: regulator

## Sources

- FDA platform technology designation: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Synaffix (Lonza)](https://onco.cc/companies/synaffix/)
- terms: [Linker (ADC)](https://onco.cc/terms/linker/), [Payload (ADC)](https://onco.cc/terms/payload/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-adc-platform-designation.json